Brian Goodman

Dr. Brian Goodman is a Partner at MPM and BioImpact Capital, an affiliate manager of MPM. He is responsible for leading investments and new company creation activities. He is a co-founder of Aktis Oncology and ReNAgade Therapeutics and serves as a member of the Board of Directors at Antiva Biosciences, and Orna Therapeutics. He has also played key leadership roles at portfolio companies during the early stages of development, including at Orna and ReNAgade leading Business Development and at Aktis Oncology as Chief Operations Officer and Chief Business Officer. Prior to joining MPM and BioImpact Capital, Brian co-founded Evelo Biosciences (NASDAQ: EVLO) and served as Head of Technology and Innovation. Before taking the operational role at Evelo, Brian was a Senior Associate at Flagship Pioneering. Brian has worked across a diverse span of science, drug discovery, development areas including the microbiome, extracellular vesicles, nonviral delivery, RNA medicines, and radiopharmaceuticals. He is an inventor on multiple patent applications. Brian holds a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School, and B.S. and B.A. degrees in biochemistry and economics, respectively, from Brandeis University.